Share this article on:

Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France

Drylewicz, Juliaa,b; Matheron, Sophiec; Lazaro, Estibalizd; Damond, Florencec; Bonnet, Fabriced; Simon, Françoise; Dabis, Françoisa,b; Brun-Vezinet, Françoisec; Chêne, Genevièvea,b; Thiébaut, Rodolphea,b

doi: 10.1097/QAD.0b013e3282f4ddfc
Basic Science

Background: HIV-2 is known to be less pathogenic than HIV-1, although the underlying mechanisms are still debated. We compared the changes over time in viro-immunological markers in HIV-1 and HIV-2-infected patients living in France during natural history and after initiation of the first combination antiretroviral therapy (CART).

Method: Patients were included in the ANRS CO3 HIV-1 cohort (N = 6707) or the ANRS CO5 HIV-2 cohort (N = 572). HIV-1-infected patients were matched to HIV-2 patients according to sex, age, HIV transmission group and period of treatment initiation. Changes in markers were estimated using linear mixed models.

Results: Analyses were performed for three groups of patients: those with estimated date of contamination (98 HIV-1 and 49 HIV-2-seroincident patients); untreated seroprevalent patients (320 HIV-1 and 160 HIV-2); and those initiating a first CART (59 HIV-1 and 63 HIV-2). In group 1, CD4 T-cell counts decreased less rapidly in HIV-2 than HIV-1 patients (−9 versus −49 cells/μl per year, P < 10−4). Results were similar in group 2. Baseline CD4 cell count at CART initiation was not different according to the type of infection. During the first 2 months of treatment, the CD4 cell count increased by +59 cells/μl per month (CI 34; 84) for HIV-1 and +24 (CI 6; 42) for HIV-2. The plasma viral load drop was threefold more important in HIV-1 patients: −1.56 log10/ml per month versus −0.62 among HIV-2 patients (P < 10−4).

Conclusion: Differences between the two infections during natural history are similar to those previously described in Africa. Once treatment is started, response is poorer in HIV-2 than in HIV-1 patients.

From the aINSERM, U875 “Epidemiology and Biostatistics”, Bordeaux F-33076, France

bBordeaux 2 University, ISPED, Bordeaux F-33076, France

cBichat Claude Bernard Hospital, Assistance Publique des Hôpitaux de Paris, Paris F-75018, France

dBordeaux University Hospital, Bordeaux F-33000, France

eCharles Nicolle Hospital, Rouen F-76000, France.

Received 1 August, 2007

Revised 16 October, 2007

Accepted 26 November, 2007

Correspondence to Rodolphe Thiébaut, INSERM U897, ISPED – Université Bordeaux 2, 146 Rue Léo Saignat, 33076 Bordeaux, France. Tel: +33 5 57 57 45 21; fax: +33 5 56 24 00 81; e-mail:

Back to Top | Article Outline


HIV-2 is endemic in West Africa and sporadic in the rest of the world [1–4]. Compared with individuals infected by HIV-1, those infected by HIV-2 have a slower clinical progression [5], a lower mortality rate for patients with high CD4 T lymphocyte counts [6–7] and lower rates of transmission [8–11]. In west African countries, comparisons have shown a slower CD4 cell depletion [11–13] and a lower plasma viral load in HIV-2-infected patients [13–20]. At the AIDS stage, HIV-2-infected patients tend to have higher CD4 cell count [15] and clinical manifestations may differ between the two infections [16,17]. Several hypotheses have been suggested to explain the differences between the two infections: lower virulence of HIV-2 [21,22], lower replication capacity of HIV-2 [23–27], better immune control [28–33] and lower activation of the immune system during HIV-2 infection [12,23,28,34]. These factors might be associated as cell activation is linked to viral load [34]. Cell responsiveness to activation might also vary [5,35].

All reported differences in the rate of disease progression between the two infections are from cohort studies performed in sub-Saharan Africa. No direct comparison has been made in Europe or the United States during the course of the infection, although the environment may play a role in the difference of pathogenicity between the two infections. For example, the level of lymphocyte activation is higher in Africa than in Europe [36], consequently the role of activation in the difference between the two infections may be weaker or even reinforced because of different background rates. Therefore, we hypothesized that the differences in viro-immunological marker levels and evolution could be different in Europe compared with sub-Saharan Africa.

Here, we report the changes in plasma HIV RNA, CD4 and CD8 cell counts over time in the French national cohort of HIV-2-infected adult patients compared with individually matched HIV-1-infected patients from the French Aquitaine Cohort.

Back to Top | Article Outline


HIV cohorts

Data are taken from the ANRS CO5 HIV-2 cohort [37] and the ANRS CO3 Aquitaine cohort [38]. The ANRS CO5 HIV-2 cohort is an ongoing national prospective study initiated in 1994 in 111 clinical centres in France. Inclusion criteria to the cohort are HIV-2 infection only, age 18 years or greater, residence in France planned for at least one year and informed consent available. The ANRS CO3 Aquitaine cohort is an ongoing prospective study initiated in 1987. Inclusion criteria are HIV-1 infection in patients aged over 18 years, and informed consent available. In the two cohorts, clinical, epidemiological and therapeutic data are collected by standardized questionnaires at each visit to the hospital (every 3–6 months according to clinical, immunovirological and therapeutic status).

Back to Top | Article Outline

Marker quantifications

CD4 cell count was performed by flow cytometry in the two cohorts. Plasma HIV-1 RNA was quantified mainly by branched DNA assays (Chiron Quantiplex RNA HIV-1, Emeryville, California, USA) with detection limits of 2.7 log10 copies/ml (500 copies/ml) or 1.7 log10 copies/ml (50 copies/ml). Although there is one commercial kit designed for HIV-1, which can also quantify only HIV-2 subtype A RNA, there is no commercial assay specifically designed for HIV-2 viral load [39]. Plasma HIV-2 RNA quantification was performed using HIV-2 strain NIHZ as a standard (Advanced Biotechnologies Inc., Columbia, Maryland, USA) with lower detection limits of either 2.4 log10 copies/ml (250 copies/ml) [40] or 2.0 log10 copies/ml (100 copies/ml) [41].

Back to Top | Article Outline

Study populations

We defined three study populations in each cohort: (i) seroincident patients; (ii) seroprevalent patients; and (iii) naive patients starting combination antiretroviral therapy (CART; combination of two nucleoside inhibitors and one protease inhibitor or three nucleoside inhibitors). The seroincident group included all seropositive patients whose date of seroconversion was known or well estimated, based on the period between the last negative and the first positive antibody test of less than 3 years. This population was defined retrospectively according to the availability of negative serology in the patients already included in each cohort. Data were collected from date of seroconversion and censored after 3 years of follow-up to avoid any informative dropout [42]. In this group, no patient started antiretroviral treatment or died before the censoring date. The seroprevalent group included all seropositive untreated patients, and without documented date of HIV infection. Data were collected from inclusion and were censored if the patient started antiretroviral treatment or died. The last group included all HIV antiretroviral-naive patients who started antiretroviral therapy consisting of at least three antiretroviral drugs. Data were collected from the date of the first CART regimen initiation and were censored if the antiretroviral treatment was modified or if the patient died. An intent-to-continue analysis was also performed and results were similar (data not shown).

HIV-1-infected patients were individually matched to HIV-2-infected patients according to factors known to be associated with HIV-1 disease progression [38,42–44]. We considered: sex, HIV transmission group (in four categories: heterosexual, homosexual, blood recipients and other), period of treatment initiation (in two categories: 1996–2000 and 2001–2005 according to the generation of available treatment) and age (in four categories: ≤ 30, 31–40, 41–50 and > 50 years) at seroconversion (for group 1), at cohort inclusion (for group 2) and at first CART regimen initiation (for group 3). For each HIV-2-infected patient, one (for group 3) to two (for groups 1 and 2) HIV-1-infected patients were randomly selected for matching among eligible candidates. We selected only one HIV-1 patient for each HIV-2 patient in group 3 because of the restricted number of available patients. All HIV-1-infected patients who were prescribed a non-nucleoside inhibitor in their CART regimen were excluded, this class of antiretroviral drugs not being active against HIV-2 infection [45].

We carried out two subanalyses to account for additional factors. For group 2, in addition to sex, age and HIV transmission group, we constituted a new study population by matching for country of birth (west Africa, Europe and others). This subanalysis was not feasible in groups 1 and 3 because of the restricted number of available patients. In group 3, we performed an additional match according to the baseline plasma viral load at treatment initiation (> 3.5 versus ≤ 3.5 log10 copies/ml).

Back to Top | Article Outline

Statistical analysis

Changes in biological markers were studied using piecewise linear mixed models. The baseline (t = 0) was the date of seroconversion for group 1, the date of inclusion for group 2 and the date of first CART regimen initiation for group 3. Trends in the evolution of markers were fitted using one slope (in unit/year) for the first two groups. For the last group of treated patients, two slopes were considered: one for the early change (in unit/month) and a second for the long-term trend (in unit/year). The time taken for the slope to change (t = 2 months) was determined for all patients by a likelihood profile. The correlation between individual baseline value(s) and the subsequent slope(s) was handled through the unstructured covariance matrix of random effects. The left-censoring of plasma viral load as a result of undetectable values was taken into account using a maximum likelihood method as previously described [46]. Adjustment for the type of assay used to quantify viral load did not modify the estimates of the slopes (data not shown). Data analyses were conducted using SAS 8.1 (SAS Institute, Cary, North Carolina, USA).

Back to Top | Article Outline


Study population

In January 2006, the ANRS CO5 HIV-2 cohort had recruited 572 patients. Of these, 89 were seroincident patients, of whom 49 were antiretroviral naive at inclusion in the cohort (group 1). Among the 483 seroprevalent patients, 160 had no history of any antiretroviral treatment (group 2). Of the 572 patients, 105 started an antiretroviral regimen, of whom 63 received CART (group 3). By January 2006, 6707 HIV-1-infected patients had been recruited into the ANRS CO3 Aquitaine cohort. The date of seroconversion was well estimated for 1464 patients including 962 who were antiretroviral naive. Among the entire cohort, 1036 patients started the CART regimen without any previous exposure to antiretroviral agents. A total of 98 HIV-1 and 49 HIV-2-seroincident patients, 320 HIV-1 and 160 HIV-2-seroprevalent patients and 59 HIV-1 and 63 HIV-2 CART-treated patients were included (Fig. 1). Study populations are described in Table 1.

Back to Top | Article Outline

Seroincident patients

The median delay between seroconversion and the first available laboratory measure was significantly shorter for HIV-1-infected patients than for HIV-2 (Table 2): 4.1 years versus 6.8 years (P < 10−4). Without administrative censoring, the median follow-up was 36 and 81 months for HIV-1 and HIV-2, respectively. During the first 3 years of follow-up, a median of four biological measurements per patient were available among HIV-1 and HIV-2 patients. The proportion of undetectable viral load measures were 14 and 85% in HIV-1 and HIV-2-infected patients, respectively. At enrolment in the cohort, the median viral load was 4.11 log10 copies/ml for HIV-1 and 2.09 log10 copies/ml for HIV-2 and the median CD4 cell counts were 399 and 585 cells/μl for HIV-1 and HIV-2, respectively.

The mean slopes estimated using linear mixed models were as shown in Table 3. The CD4 cell count and CD4 cell percentage decreased significantly in the HIV-1 group (−49 cells/μl per year and −1.01%/year) but was quite stable in the HIV-2 group (−9 cells/μl per year and −0.04%/year). On average, the plasma viral load was quite stable over time in the HIV-1 group and in HIV-2 (−0.02 and +0.06 log10 copies/ml per year, respectively). The CD8 cell count did not change significantly in either group (Table 2). Therefore, the CD4: CD8 cell ratio decreased significantly in the HIV-1 group (−0.06/year), whereas it did not change in the HIV-2 group (0.02/year, P < 10−4).

Back to Top | Article Outline

Seroprevalent patients

The median delay between inclusion in the study and the first measurement of the CD4 cell count was 2 months for HIV-1 and 6 months for HIV-2. During the follow-up (median of 4.9 years for HIV-1 and 2.9 for HIV-2), a median of four measurements were available for HIV-1 and seven for HIV-2. At inclusion in the study, the proportion of patients with undetectable plasma viral loads was 9 and 39% for HIV-1 and HIV-2, respectively.

At enrolment into the cohorts, the median CD4 cell count was significantly lower in HIV-2 than in HIV-1 patients: 260 cells/μl versus 324 (P = 0.007), probably reflecting the later enrolment of HIV-2 patients compared with HIV-1 patients. The median plasma viral load was, however, still significantly lower in HIV-2 (2.62 versus 4.39 log10 copies/ml, P < 10−4) as well as the median CD8 cell count (P = 0.0005).

The estimated average decrease in CD4 cell count was 4.5-fold more pronounced in HIV-1: −49 cells/μl per year than HIV-2: −11 (P = 0.003, Table 3). The CD4 cell percentage decrease was not significantly different between the two groups (P = 0.70). There was a small insubstantial increase in plasma viral load in the two groups: +0.20 log10 copies/ml per year for HIV-1 and +0.14 for HIV-2. Therefore, the plasma viral load was still very different in the two populations after one year of follow-up (difference of 1 log10 copies/ml, P = 0.005). The increase in the CD8 cell count did not differ between the two groups (P = 0.44). The CD4: CD8 cell ratio decreased over time in the two groups, but was more pronounced in the HIV-1 group: −0.06/year versus −0.02 (P = 10−4). We performed a second match including country of birth as a matching variable and the results were similar. In addition, we looked at any modification of the effect of the type of infection (HIV-1 or HIV-2) on the slopes of each marker according to the country of birth, and none were significant.

Back to Top | Article Outline

Patients starting combined antiretroviral treatment regimen

At the initiation of CART, the observed median CD4 cell count was not significantly different in the two groups (Table 2, P = 0.06), as well as the CD4 cell percentage (P = 0.70). The plasma viral load was significantly higher in the HIV-1 group (P < 10−4). During the first 2 months of CART, the decline in plasma viral load was threefold steeper in the HIV-1 group (−1.56 versus −0.62 log10 copies/ml per month, P < 10−4). The increases in CD4 cell count and CD4 cell percentage were more pronounced in the HIV-1 group (+59 cells/μl per month versus +24 for HIV-2, Table 3). The CD8 cell count was stable and did not differ significantly between the two groups (P = 0.26). The CD4: CD8 cell ratio increased significantly in the two groups: +0.11/month for HIV-1 versus +0.06 for HIV-2.

After the first 2 months of CART, in HIV-1-infected patients, the CD4 cell count and CD4 cell percentage continued to increase:+46 cells/μl per year and +3.3%/year, respectively. Plasma HIV RNA: −1.13 log10 copies/ml per year and CD8 cell count: −100 cells/μl per year decreased slightly. Therefore, the CD4: CD8 cell ratio increased significantly: +0.16/year. In HIV-2-infected patients, all these markers were stable (Table 4). There was no further increase in the CD4 cell count (−2.88 cells/μl per year). Among the 24 patients (60%) who reached a viral load below 2.7 log10 copies/ml without rebound during the first 6 months of follow-up, the slope of CD4 cell count was also stable (+18 cells/μl per year, P = 0.50). In the 34 HIV-1-infected patients (77%) who achieved the same viral load target, the CD4 cell increase was still greater (+59 cells/μl per year, P < 0.0001).

Changes in markers were not modified according to the treatment type, i.e. with or without protease inhibitor (data not shown). In a secondary analysis, we matched patients according to a plasma viral load greater than 3.5 log10 copies/ml (54% of HIV-1 and 24% of HIV-2 patients) and the results were similar.

Back to Top | Article Outline


We compared the changes in viro-immunological markers between individuals infected with HIV-2 and individuals infected with HIV-1, all being followed in France. During the natural history of infection, the estimated rates of CD4 cell decrease were much more pronounced in HIV-1-infected patients compared with HIV-2-infected patients. Furthermore, the estimated slopes were noticeably similar in seroprevalent and seroincident patients (−49 cells/μl per year for HIV-1 and −9 for HIV-2, Fig. 2). The plasma viral load always remained higher in HIV-1 patients compared with HIV-2 patients with the difference varying from 1.1 log10 copies/ml in seroincident patients to 2.2 log10 copies/ml in the patients initiating CART. Differences in the CD8 cell count mirrored the differences in the plasma viral load. Although a formal comparison with studies performed in Africa is difficult because of the great variability in the dates of enrolment since the onset of infection, reported differences in the present study look similar to those performed in Africa [12,13,18–20,23,24,26,33,47,48]. In seroprevalent cohorts of patients not treated with antiretroviral drugs, the reported differences in HIV RNA varied between 1.5 log10 and 3.3 log10, and between 50 and 400 cells/μl for the CD4 cell count [23,24,47,48]. The average difference of each marker between the seroincident HIV-1 and HIV-2 groups in the present study were also similar to those reported in a seroincident cohort of female sex workers in Senegal [18].

A novel aspect of this study is the estimation of slopes for each marker. Here again, these estimations were similar to those reported in Senegal [48], with a decline of 13% in the T-cell count in HIV-1-infected patients (16% in Senegal [48]) and 3.7% in HIV-2-infected patients (4.1% in Senegal [48]). Gottlieb et al. [48], however, reported similar slopes in both infections when controlling for plasma viral load levels. In our study, however, neither the baseline plasma viral load (according to the following categories: < 2.7, 2.7–3.7, > 3.7, P = 0.44) nor the baseline CD4 cell count (< 200, 200–500, > 500, P = 0.17) influenced the effect of either HIV-1 or HIV-2 on CD4 cell slopes in seroprevalent patients. In other words, the differences in CD4 cell count decline between the two infections were similar whatever the viral load or CD4 cell count at the time of enrolment into the cohort.

The difference in pathogenicity between the two types of virus may be independent of environment because, in this study, the differences between the natural history of HIV-1 and HIV-2 infection were similar for patients from the same geographical area. This study did not, however, explore the respective roles of the host and the virus in determining the differences between the two infections. Whether differences in pathogenicity are mainly caused by viral replication, viral infectivity, cell susceptibility to activation, or cytotoxic T-lymphocyte response remains unknown.

The virological response to CART was weaker in HIV-2 patients whatever the initial HIV-RNA level. This result has previously been reported in Africa, Europe and the United States [49–54]. In Abidjan (Côte d'Ivoire), Adjé-Touré et al. [51] reported a median viral load decrease of −0.6 log10 copies/ml and an increase of +80 cells/μl for CD4 cell count, 2 months after the beginning of therapy in HIV-2-treated patients. The cause of this poor immunological response to treatment is a matter of debate [49], the first hypothesis being the limited impact of antiretroviral drugs on in-vivo HIV-2 replication. It is difficult to distinguish whether the poorer in-vivo response in HIV-2 patients might be linked to the potency of antiretroviral drugs [51,53,55] or to pathogenic features of HIV-2 infection such as the low replicative capacity [27,56]. The 50% divergence in protease gene nucleotides between the two types of infection could explain the reduced susceptibility of HIV-2 to the protease inhibitors developed for HIV-1-infected patients [49,56]. It is also clear that the potency against HIV-2 differs for each individual protease inhibitor [55,57] and that resistance may occur [51,58–61]. Some of these resistances are similar to those observed in HIV-1 infection [54,62] but others differ (e.g. Q151M), leading to the hypothesis that the preferred pathway for resistance development may be different between the two viruses [63]. It could be expected that a more potent regimen leading to better virological control would improve the global response to treatment. The CD4 cell count did not, however, increase in response to treatment in HIV-2 patients with controlled viral load during the first 6 months. It should also be noted that HIV-2 patients started an antiretroviral treatment at the same CD4 cell count as HIV-1 patients, so they started therapy after a longer duration of infection. This late initiation of antiretroviral therapy in HIV-2 infection might contribute to the poorer response to treatment in particular in the CD4 cell increase. Therefore, the findings of the present study are in favour of an earlier initiation of HAART treatment in HIV-2-infected patients.

Several limits of this study should be recognized. First, the individual matching was limited to a restricted number of potential confounding factors. We were not able to match for country of birth in all analyses because of the restricted number of patients from west Africa in the Aquitaine cohort. We could, however, perform such matching for the seroprevalent group and the results were similar. Another limitation was the censoring of follow-up because of a change in treatment or death. This may lead to biased estimates of the change in viro-immunological markers. The consistency in the estimates of the slopes for each marker between the seroprevalent and seroincident groups, although the censoring was only administrative for this latter group (3 years of follow-up), argues in favour of the validity of estimates. Finally, the large number of HIV-2-infected patients with undetectable viral loads yielded insufficient information to estimate the slopes reliably. Therefore, blunted variations in HIV-RNA viral load (lower than the usual measurement of 0.5 log10 copies/ml) need to be explored with more sensitive assays.

In conclusion, this study, the first comparing the evolution of markers between HIV-1 and HIV-2-infected patients outside of Africa, found similar differences between the two infections in Europe and in sub-Saharan Africa. Although the difference in viral load is consistent across all analyses, the biological mechanism is still a matter of debate. The reduced response to CART in HIV-2-infected patients raises the question of optimal antiretroviral drug regimens and the right time to initiate treatment in HIV-2 infection. A better understanding of the differences in pathogenicity between the two infections may lead to improvements in treating both of them.

Back to Top | Article Outline


The authors gratefully thank Delali Sefe for editing the English in this paper.

Back to Top | Article Outline

Composition of the ANRS CO3 Aquitaine cohort

Scientific committee: R. Salamon (chair), J. Beylot, M. Dupon, M. Longy-Boursier, J.L. Pellegrin, J.M. Ragnaud

Coordinator: F. Dabis

Epidemiology: G. Chêne, F. Dabis, S. Lawson-Ayayi, C. Lewden, R. Thiébaut, M. Winnock

Medical coordinator: Dr M. Bonareck (Bordeaux), Dr F. Bonnal (Bordeaux), Dr F. Bonnet (Bordeaux), Dr N. Bernard (Bordeaux), Dr O. Caubet (Bordeaux), Dr L. Caunègre (Dax), Dr J. Ceccaldi (Libourne), Pr P. Couzigou (Bordeaux), Dr C. De La Taille (Bordeaux), Dr S. De Witte (Mont de Marsan), Pr M. Dupon (Bordeaux), Dr H. Dutronc (Bordeaux), Dr S. Farbos (Bayonne), Dr T. Galpérine (Bordeaux), Dr K. Lacombe (Bordeaux), Dr D. Lacoste (Bordeaux), Dr S. Lafarie (Bordeaux), Dr P. Loste (Dax), Pr D. Malvy (Bordeaux), Pr P. Mercié (Bordeaux), Pr P. Morlat (Bordeaux), Pr D. Neau (Bordeaux), Dr A. Ochoa (Bordeaux), Pr J.L. Pellegrin (Bordeaux), Pr J.M. Ragnaud (Bordeaux), Dr S. Tchamgoué (Libourne), Pr J.F. Viallard (Bordeaux)

Virological coordinator: Pr H. Fleury (Bordeaux), Pr M.E. Lafon (Bordeaux), Dr B. Masquelier (Bordeaux), Dr I. Pellegrin (Bordeaux)

Clinical pharmacology: Pr D. Breilh (Bordeaux)

Pharmacovigilance: Dr G. Miremont-Salamé (Bordeaux)

Immunology: Dr P. Blanco (Bordeaux), Pr J.F. Moreau (Bordeaux)

Data management and statistical analysis: E. Balestre, M.J. Blaizeau, M. Decoin, S. Delveaux, L. Dequae-Merchadou, C. Hannapier, S. Geffard, S. Labarrère, V. Lavignolle-Aurillac, B. Uwamaliya-Nziyumvira

Technical team: J. Lemonnier, D. Touchard, H. Zouari, B. Boulant, N. Boulant, D. Dutoit, L. Houinou

Back to Top | Article Outline

Composition of the ANRS CO5 HIV-2 cohort

Investigator coordinator: S. Matheron (Hôpital Bichat Claude Bernard, Paris)

Virological coordinators: F. Brun-Vezinet, F. Damond (Hôpital Bichat Claude Bernard, Paris)

Methodological coordinator: G. Chêne, A. Bénard (INSERM U897, Bordeaux)

Clinical investigators: M. Beaufils, I. Lecomte, (Tenon, Paris); C. Boitard, L. Roudière, J.P. Viard (Necker, Paris); P.M. Girard, M.C. Meyohas, D. Bollens, D. Berriot, F. Besse, P. Tangre, M. Kirsteter (St Antoine, Paris); J.B. Dubuisson, A. Compagnucci, L. Finkielsztejn (Port Royal, Paris); D. Sicard, C. Bernasconi, O. Zak dit Zbar (Cochin, Paris); W. Rozenbaum, C. Lascoux-Combe, I. Donadieu, A. Coridian, S. Thevenet, S. Courtial-Destembert (Tenon, Paris); J. Gilquin (St Joseph, Paris); J.L. Vildé, P. Longuet, W. Nouioua, G. Breton, C. Charlois (Bichat, Paris); J.P. Coulaud, S. Matheron, A. Leprêtre, S. Mas, G. Moreau, P. Campa, E. Bouvet, S. Fegueux, V. Joly, S. Lariven, P.H. Consigny, I. Fournier, R. Landman, C. Voyer, G. Benabdelmoumen, C. Gaudebout, P. Yéni (Bichat, Paris); F. Bricaire, R. Tubiana, V. Zeller, M. Pauchard (Pitié Salpêtrière, Paris); F. Meier, E. Mortier, C. Chandemerle (L. Mourier, Colombes); C. Perronne, J.C. Melchior, P. de Truchis (R. Poincaré, Garches); D. Mechali, M.A. Khuong-Josse, T. Labergère, B. Taverne (Delafontaine, Saint Denis); A. Krivitzky, M. Bentata, J.P. Pathé, F. Rouges, A. Mosnier, P. Honoré-Berlureau (Avicenne, Bobigny); P. Morel, F.J. Timsit, E. Spindler (St Louis, Paris); M. Thomas, H. Mouas, V. Jeantils (J. Verdier, Bondy); O. Patey, C. Semaille, L. Richier(Villeneuve St Georges); J.F. Delfraissy, C.Goujard, C. Rousseau, Y. Quertainmont, T. Rannou (Bicêtre, Le Kremlin Bicêtre); J.P. Clauvel, L. Oksenhendler, L. Gérard (St Louis, Paris); M. Beumont-Mauriel, G. Cessot (Institut A. Fournier, Paris); P. Vinceneux, M. Bloch, E. Lafon, A.M. SimonPoli (L. Mourier, Colombes); P. Lagarde, F. David-Ouaknine, E. Froguel, P. Simon (Lagny sur Marne); P. Mornet, Y. Welker (St Germain en Laye); M. Ruel, K. Chemlal (M. Fourestier, Nanterre); F. Lionnet, P. Genet (V. Dupouy, Argenteuil); P. Polomeni, A. Leprêtre (E. Roux, Eaubonne); T. Papo (Bichat, Paris); J.M. Decazes, D. Ponscarme, F. Bani-Sadr, N. Colin Deverdière (St Louis, Paris); O. Blétry, D. Zucman, C. Majerholc (Foch, Suresnes); D. Champetier de Ribes, G. Force (Perpétuel Secours, Levallois); S. Herson, N. Amirate, A. Coutelier, M. Brançon (Pitié Salpêtrière, Paris); P.Y. Redelsperger, B. Ponge (M. Jacquet, Melun); J.P. Escande, N. Dupin (Tarnier, Paris); M. Kazatchkine, M. Karmochkine, L. Weiss, D. Batisse, C. Picketty, S. Marinier-Roger, D. Tisne-Dessus (HEGP, Paris); M. Chousterman, V. Garrait, L. Richier (Intercommunal, Créteil); D. Hillion, H. Masson (Poissy); O. Danne, L. Blum, M. Eouzan (Pontoise); A. Sobel, Y. Lévy, P. Lesprit, F. Bourdillon, C. Jung (H. Mondor, Créteil); G. Guermonprez, A. Dulioust, P. Chardon (CMC de Bligny, Briis sous Forges); G. Raguin, M. Karmochkine (La Croix St Simon, Paris); F. Bournerias (St Cloud); F. Granier, V. Perronne (F. Quesnay, Mantes la Jolie); C. Lejeune, P. Bellaiche (HEGP, Paris) M. Janowski, C. Winter (Intercommunal, Montreuil); C. Vilain, I. La Torre (Montargis); G. Naudin (Diaconnesses, Paris); G. Tobelem, J. Cervoni, J.M. Zini (Lariboisière, Paris); D. Sereni, C. Lascoux-Combe, F. Prévoteau du Clary, C. Pintado (St Louis, Paris); J. Molina, D. Ponscarme, M. Lafaurie (St Louis, Paris); P. Brunet (Arpajon); B. Godeau, A. Schaeffer (H. Mondor, Créteil); G. Charpentier, A. Devidas, P. Chevojon, P. Kousignian, C. Petitdidier, Y. Lemercier, I. Turpault (Corbeil); E. Rouveix, S. Daum-Morelon (A. Paré, Boulogne); P. At Khen, I. Bouchard (Etablissement public de santé national, Fresnes); R. Stein Metzer, S. Kernbaum (Hôpital Américain, Neuilly); B. Gachot (Institut Pasteur, Paris); P. Bourdon, J.L. Delassus (R. Balanger, Aulnay); M. Gayraud, L. Bodard, L. Raffenne (Institut Mutualiste Montsouris, Paris); H. Sors, D. Israël-Biet (HEGP, Paris); R. Roué, P. Imbert (Bégin, St Mandé); P. Galanaud, F. Boué, D. Emilie, A.M. Delavalle (A. Béclère, Clamard); L. Guillevin, O. Launay, L. Belarbi (Avicenne, Bobigny); G. Beck-Wirth, C. Beck (Mulhouse); J. Barrier, F. Raffi, E. Billau (Hotel Dieu, Nantes); J.F. Stalder, B. Milpied (Hotel Dieu, Nantes); R. Laurent, C. Drobacheff, D. Bourezane (St Jacques, Besançon); C. Trépo, L. Cotte, C. Brochier (Hotel Dieu, Lyon); A.P. Blanc, T. Allègre (Aix en Provence); J.A. Gastaud, M.P. Drogoul, M. Fabre (Régional, Marseille); G. Dien, C. Daniel, A. Hascouet (Saint Brieuc); P. Granier (Fleyriat, Bourg en Bresse); P. Choutet, J.M. Bestnier, D. Vautier (Bretonneau, Tours); F. Caron, F. Borsa Lebas, Y. Debab (C. Nicolle, Rouen); C. Brambilla, P. Leclerc (Michalon, Grenoble); M. Mornet, G. Adam (J. Coeur, Bourges); J.P. Delmont, J. Moreau, P. Brouqui (Nord, Marseille); T. Cartier, F. Andrieux, C. Bouvier (Pontchaillou, Rennes); M.H. Delangle, B. Héry (St Nazaire); B. Becq-Giaudon, J.P. Breux (J. Bernard, Poitiers); P. Arsac (Régional, Orléans); A. Lafeuillade (Chalucet, Toulon); J.M. Ragnaud (Pellegrin Tripode, Bordeaux); M.J. Chantereau, S. Durupatient (W. Morey, Chalon sur Saône); P. Perré (La Roche sur Yon); M. Langlois (Villefranche de Rouergue); M. Dupon, H. Dutronc (Pellegrin Tripode, Bordeaux); J.L. Pellegrin, P. Mercié (Haut Lévêque, Bordeaux Pessac); P. Simonet, B. Vialatte (Cannes); T. May, L. Boyer (Nancy Brabois, Vandoeuvre les Nancy); B. Manoury, M. Daumal (St Quentin); F. Janbon, J. Reynes, M. Vidal (Montpellier); J.L. Schmit, A. Smail (Amiens Nord, Amiens); H. Jardel, Y. Poinsignon, D. Le Pichon (P. Chubert, Vannes); J. Beytout, C. Jacomet, F. Gourdon (Hotel Dieu, Clermont Ferrand); H. Portier, M. Buisson, M. Greusard (Bocage, Dijon); Y. Mouton, F. Ajana, V. Baclet (Dron, Tourcoing); L. Yver, Y. Turpin (Angoulême); M. Uzan, D. Garipuy (J. Ducuing, Toulouse); M. Bonnefoy, A. Riché (Angoulême).

Virological investigators: F. Brun-Vézinet, F. Damond (Bichat, Paris); F. Ferchal, P. Palmer (St Louis, Paris); L. Morand-Joubert (St Antoine, Paris); D. Cottalorda (F. de médecine, Nice); M.P. Schmitt (F. de médecine, Strasbourg); P. Billaudel, V. Ferre (Institut de Biologie, Nantes); P. Lab, A. Bassignot (Besançon); P. Barin (Bretonneau, Tours); P. Boulanger, D. Tardy (Université, Lyon); D. Raoult, C. Tamalet (La Timone, Marseille); P. Avril, M. Kerriguy (Pontchaillou, Rennes); J. Puel, A. Jaafar (Purpan, Toulouse); P. Buffet-Janvresse (C. Nicolle, Rouen); P. Seigneurin, D. Morand (Grenoble); P. Agius, M. Bourgoin (J. Bourgoin, Poitiers); P. Fleury, B. Masquelier (Pellegrin Tripode, Bordeaux); D. Duverlie, M. Roussel (Amiens); H. La Feuille, D. Henquell (F. de médecine, Clermond Ferrand); A. Chiacha (St Michel, Angoulême); D. Trevoux, D. Delarbre (Mulhouse); C. Brehant, M. Marty (La Rochelle); P. Watry, D. Bocket (Lille); B. Montes (St Eloi, Montpellier).

Data management and statistical analysis: P. Campa, A. Kissila, V. El Fouikar, A. Taieb

Conflicts of interest: None.

Back to Top | Article Outline


1. Chang LW, Osei-Kwasi M, Boakye D, Aidoo S, Hagy A, Curran JW, et al. HIV-1 and HIV-2 seroprevalence and risk factors among hospital outpatients in the Eastern Region of Ghana, West Africa. J Acquir Immune Defic Syndr 2002; 29:511–516.
2. Diop OM, Pison G, Diouf I, Enel C, Lagarde E. Incidence of HIV-1 and HIV-2 infections in a rural community in southern Senegal. AIDS 2000; 14:1671–1672.
3. Schim van der Loeff MF, Akum AA, Sarge-Njie R, Van der Sande M, Jaye A, Sabbaly S, et al. Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2. Int J Epidemiol 2006; 35:1322–1328.
4. Semaille C, Barin F, Cazein F, Pillonel J, Lot F, Brand D, et al. Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France. J Infect Dis 2007; 196:377–383.
5. Rowland-Jones SL, Whittle DH. Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? Nat Immunol 2007; 8:329–331.
6. Schim van der Loeff MF, Jaffar S, Aveika AA, Sabally S, Corrah T, Harding E, et al. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in the Gambia. AIDS 2002; 16:1775–1783.
7. Hansmann A, Schim van der Loeff MF, Kaye S, Awasana AA, Sarge-Njie R, O'Donovan D, et al. Baseline plasma viral load and CD4 Cell percentage predict survival in HIV-1 and HIV-2 infected women in a community-based cohort in the Gambia. J Acquir Immune Defic Syndr 2005; 38:335–341.
8. Whittle CH, Ariyoshi K, Rowland-Jones S. HIV-2 and T cell recognition. Curr Opin Immunol 1998; 10:382–387.
9. Adjololo-Johnson G, DeCock KM, Ekpini E, Velter KM, Sibailly T, Brattegaard K, et al. Prospective comparison of mother to child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272:462–466.
10. Kanki PJ, Travers KU, Mboup S, Hsieh CC, Marlink RG, Gueye-Ndiaye A, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943–946.
11. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587–1590.
12. Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R, et al. Low peripheral blood HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol 1998; 1:457–468.
13. Jaffar S, Wilkins A, Ngom PT, Sabally S, Corrah T, Bangali JE, et al. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:327–332.
14. Michel P, Balde AT, Roussilhon C, Aribot G, Sarthou JL, Gougeon ML. Reduced immune activation and T cell apoptosis in human immunodeficiency virus type 2 compared with type 1: correlation of T cell apoptosis with β2 microglobulin concentration and disease evolution. J Infect Dis 2000; 181:64–75.
15. Martinez-Steele E, Awasana AA, Corrah T, Sabally S, Van der Sande M, Jaye A, et al. Is HIV-2 induced AIDS different from HIV-1 associated AIDS? Data from a West African clinic. AIDS 2007; 21:317–324.
16. Ndour M, Sow PS, Coll-Seck AM, Badine S, Ndour CT, Diakhaté N, et al. AIDS caused by HIV1 and HIV2 infection: are there clinical differences? Results of AIDS surveillance 1986-97 at Fann Hospital in Dakar, Senegal. Trop Med Int Health 2000; 5:687–691.
17. Matheron S, Mendoza-Sassi G, Simon F, Olivares R, Coulaud JP, Brun-Vezinet F. HIV-1 and HIV-2 AIDS in African patients living in Paris. AIDS 1997; 11:934–936.
18. Popper SJ, Dieng Sarr A, Travers KU, Gueye-Ndiaye A, Mboup S, Essex ME, et al. Lower Human Immunodeficiency Virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116–1121.
19. Alabi AS, Jaffar S, Ariyoshi K, Blanchard T, Schim van der Loeff M, Awasana AA, et al. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS 2003; 17:1513–1520.
20. Shanmugam V, Switzer WM, Nkengasong JN, Garcia-Lerma G, Green TA, Ekpini E, et al. Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections. J Acquir Immune Defic Syndr 2000; 24:257–263.
21. Gilbert PB, McKeague IW, Eisen G, Mullins C, Guéye-NDiaye A, Mboup S, et al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 2003; 22:573–593.
22. Looney DJ, Hayashi S, Nicklas M, Redfield RR, Broder S, Wong-Staal F, et al. Differences in the Interaction of HIV-1 and HIV-2 with CD4. J Acquir Immune Defic Syndr 1990; 3:649–657.
23. Koblavi-Dème S, Kestens L, Hanson D, Otten RA, Borget MY, Bilé C, et al. Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Côte D'Ivoire. AIDS 2004; 18:413–419.
24. Popper SJ, Dieng Sarr A, Gueye-Ndiaye A, Mboup S, Essex ME, Kanki PJ. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low viral production in vivo. J Virol 2000; 74:1554–1557.
25. Arien KK, Abraha A, Quiñones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005; 79:8979–8990.
26. Jaye A, Sarge-Njie R, Schim van der Loeff M, Todd J, Alabi A, Sabally S, et al. No differences in cellular immune responses between asymptomatic HIV type 1- and type 2- infected Gambian patients. J Infect Dis 2004; 189:498–505.
27. MacNeil A, Sarr AD, Sankale JL, Meloni ST, Mboup S, Kanki P. Direct evidence of lower viral replication rates in vivo in HIV-2 infection than HIV-1 infection. J Virol 2007; 81:5325–5330.
28. Hanson A, Dieng Sarr A, Shea A, Jones N, Mboup S, Kanki P, et al. Distinct profile of T cell activation in HIV type 2 compared to HIV type 1 infection: differential mechanism for immunoprotection. AIDS Res Hum Retroviruses 2005; 21:791–798.
29. Duvall MG, Jaye A, Dong T, Brenchley JM, Alabi AS, Jeffries DJ, et al. Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol 2006; 176:6973–6981.
30. Lopes AR, Jaye A, Dorrell L, Sabally S, Alabi A, Jones NA, et al. Greater CD8+ TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection. J Immunol 2003; 171:307–316.
31. Zheng NN, Kiviat NB, Sow PS, Hawes SE, Wilson A, Diallo-Agne H, et al. Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1 and HIV-2-infected individuals in Senegal. J Virol 2004; 78:13934–13942.
32. Nuvor SV, Van der Sande M, Rowland-Jones S, Whittle H, Jaye A. Natural killer cell function is well preserved in asymptomatic human immunodefiency virus type 2 (HIV-2) infection but similar to that of HIV-1 infection when CD4 T-cell counts fall. J Virol 2006; 80:2529–2537.
33. Chollet-Martin S, Simon F, Matheron S, Joseph CA, Elbim C, Gougerot-Pocidalo MA. Comparison of plasma cytokine levels in African patients with HIV-1 and HIV-2 infection. AIDS 1994; 8:879–884.
34. Deeks SG, Kitchen CMR, Liu L, Guo H, Gascon R, Narváez AB, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004; 104:942–947.
35. Schindler M, Munch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, et al. Nef-mediated suppression lineage that gave rise to HIV-1. Cell 2006; 125:1055–1067.
36. Eggena MP, Barugahare B, Okello M, Mutyala S, Jones N, Ma Y, et al. T-cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion and co-infection. J Infect Dis 2005; 191:694–701.
37. Matheron S, Puyeo S, Damond F, Simon F, Leprêtre A, Campa P, et al. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort. AIDS 2003; 17:2593–2601.
38. Lazaro E, Coureau G, Guedj J, Blanco P, Pellegrin I, Commenges D, et al. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antivir Ther 2006; 11:343–350.
39. Rodés B, Sheldo J, Toro C, Cuesva L, Pérez-Pastrana E, Herrera I, et al. Quantitative detextion of plasma human immunodefiency virus type 2 subtype A RNA by the Nuclisens EasyQ Assay. J Clin Microbiol 2007; 45:88–92.
40. Damond F, Gueudin M, Pueyo S, Farfara I, Robertson DL, Descamps D, et al. Plasma RNA viral load in human immunodefiency virus type 2 subtype A and subtype B infections. J Clin Microbiol 2002; 40:3654–3659.
41. Damond F, Collin G, Deschamps D, Matheron S, Pueyo S, Taieb A, et al. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J Clin Biol 2005; 43:4234–4236.
42. Touloumi G, Pantazis N, Babiker AG, Walker SA, Katsarou O, Karafoulidou A, et al, on behalf of the CASCADE Collaboration. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS 2004; 18:1697–1705.
43. CASCADE Collaboration. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1 infected individuals with well estimated dates of seroconversion. J Acquir Immune Defic Syndr 2003; 34: 76–83.
44. Thiébaut R, Jacqmin-Gadda H, Walker S, Sabin C, Prins M, Del Amo J, et al, and the CASCADE Collaboration. Determinants of response to first HAART regimen in antiretroviral-naive patients with an estimated time since HIV seroconversion. HIV Med 2006; 1:1–9.
45. Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme AM. Activity of nonnucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS 1999; 13:1477–1483.
46. Thiébaut R, Jacqmin-Gadda H. Mixed models for longitudinal left-censored repeated measures. Comput Methods Programs Biomed 2004; 74:255–260.
47. Gottlieb GS, Hawes SE, Diallo-Agne H, Stern JE, Critchlow CW, Kiviat NB, et al. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 2006; 20:895–900.
48. Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Redman M, Collsek AM, et al. Equal plasma viral load predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type-1 and HIV-2 infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905–914.
49. Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, et al, and the ANRS CO5 HIV2 Cohort Study Group. CD4 cell recovery in treated HIV-2 infected adults is lower than expected: results from the French ANRS CO5 HIV-2 Cohort [letter]. AIDS 2006; 20:459–462.
50. Mullins C, Eisen G, Popper S, Dieng Sarr A, Sankalé JL, Berger JJ, et al. Highly active antiretroviral therapy and viral response in HIV type-2 infection. Clin Infect Dis 2004; 38:1771–1779.
51. Adjé-Touré CA, Cheingsong R, Garcia-Lerma JG, Eholié S, Borget MY, Bouchez JM, et al. Antiretroviral therapy in HIV-2 infected patients: change in plasma load, CD4+ cell count and drug resistance profiles of patients in Abidjan, Côte d'Ivoire. AIDS 2003; 17:S49–S54.
52. Jallow S, Kaye S, Alabi A, Aveika A, Sarge-Njie R, Sabally S, et al. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in the Gambia [letter]. AIDS 2006; 20:1455–1458.
53. Van der Ende ME, Prins JM, Brinkman K, Keuter M, Veenstra J, Danner SA, et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2 infected patients. AIDS 2003; 17:S55–S61.
54. Smith NA, Shaw T, Berry N, Vella C, Okorafor L, Taylor D, et al. Antiretroviral therapy for HIV-2 infected patients. J Infect 2001; 42:126–133.
55. Withrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57–65.
56. Blaak H, Van der Ende ME, Boers PHM, Schuitemaker H, Osterhaus AD. In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology 2006; 353:144–154.
57. Desbois D, Peytavin G, Matheron S, Damond F, Collin G, Bénard A, et al. Phenotypic susceptibility in vitro to amprenavir, atazanavir, darunavir, lopinavir, and tipranavir of HIV-2 clinical isolates from the French ANRS HIV-2 Cohort. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February 2007. Poster # 615.
58. Rodés B, Holguin A, Soriano V, Dourana M, Mansinho K, Antunes F, et al. Emergence of drug resistance mutations in human immunodefiency virus type-2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol 2000; 38:1370–1374.
59. Van der Ende ME, Guillon C, Boers PH, Ly TD, Gruters RA, Osterhaus AD, et al. Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2000; 25:11–18.
60. Damond F, Matheron S, Peytavin G, Campa P, Taieb A, Collin G, et al. Selection of K65R mutation in HIV-2 infected patients receiving tenofovir-containing regimen. Antivir Ther 2004; 9:635–636.
61. Descamps D, Damond F, Matheron S, Collin G, Campa P, Delarue S, et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol 2004; 74:197–201.
62. Colson P, Henry M, Tourres C, Lozachmeur D, Gallais H, Gastaut JA, et al. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol 2004; 42:570–577.
63. Boyer PL, Sarafianos SG, Clark PK, Arnold E, Hughes SH. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? PLoS Pathog 2006; 2:101–111.

Cited By:

This article has been cited 6 time(s).

A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa
Gottlieb, GS; Eholié, S; Nkengasong, JN; Jallow, S; Rowland-Jones, S; Whittle, HC; Sow, PS
AIDS, 22(16): 2069-2072.
PDF (84) | CrossRef
First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration
Drylewicz, J; Eholie, S; Maiga, M; Zannou, DM; Sow, PS; Ekouevi, DK; Peterson, K; Bissagnene, E; Dabis, F; Thiébaut, R; for the International epidemiologic Databases to Evaluate AIDS (IeDEA) West Africa Collaboration,
AIDS, 24(7): 1043-1050.
PDF (210) | CrossRef
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients
Bénard, A; Damond, F; Campa, P; Peytavin, G; Descamps, D; Lascoux-Combes, C; Taieb, A; Simon, F; Autran, B; Brun-Vézinet, F; Chêne, G; Matheron, S; for the ANRS CO5 HIV-2 Cohort Study Group,
AIDS, 23(9): 1171-1173.
PDF (330) | CrossRef
HIV-2 infection: a call for controlled trials
Matheron, S
AIDS, 22(16): 2073-2074.
PDF (53) | CrossRef
Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression
Marcelino, JM; Nilsson, C; Barroso, H; Gomes, P; Borrego, P; Maltez, F; Rosado, L; Doroana, M; Antunes, F; Taveira, N
AIDS, 22(17): 2257-2265.
PDF (353) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Comparison of Early CD4 T-Cell Count in HIV-1 Seroconverters in Côte d'Ivoire and France: The ANRS PRIMO-CI and SEROCO Cohorts
Lewden, C; Thiébaut, R; Boufassa, F; Coulibaly, A; Malateste, K; Seng, R; Toni, T; Inwoley, A; Rouzioux, C; Minga, A; Anglaret, X; Meyer, L
JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(2): 260-265.
PDF (240) | CrossRef
Back to Top | Article Outline

CD4; CD8; HIV viral load; HIV-1; HIV-2; longitudinal study

© 2008 Lippincott Williams & Wilkins, Inc.